Merck & Co. never got its clot-fighting drug Zontivity off the ground, and last month, the company decided to stop promoting it in the U.S. altogether. But there's hope for Zontivity yet, now that specialty pharma Aralez has decided to pay $25 million for the privilege of picking up the baton.
